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Stem cell banks are increasingly recognized as an essential resource of biological materials for both basic and translational stem
cell research. By providing transnational access to quality controlled and ethically sourced stem cell lines, stem cell banks seek to
foster international collaboration and innovation. However, given that national stem cell banks operate under diﬀerent policy,
regulatory and commercial frameworks, the transnational sharing of stem cell materials and data can be complicating. This
paper will provide an overview of the most pressing challenges regarding the governance of stem cell banks, and the diﬃculties
in designing regulatory and commercial frameworks that foster stem cell research. Moreover, the paper will shed light on the
numerous international initiatives that have arisen to help harmonize and standardize stem cell banking and research processes to
overcome such challenges.
1.Introduction
Since the pioneering isolation and culture of human embry-
onic stem cells (hESCs) over a decade ago, a new era of
clinical promise in regenerative medicine has emerged. Stem
cell research promises to improve our ability to prevent and
cure disease by providing cells for organ transplantation and
cell therapies. It will also be used to create a successful model
system for drug discovery, including the development of
new testing methods for drug eﬃcacy, toxicity, and safety,
as well as providing a deeper understanding of the processes
of human cell diﬀerentiation for the treatment of several
diseases including cancer [1].
Stem cell research is steadily entering the clinical transla-
tion ﬁeld with the launching of the ﬁrst clinical trial (Phase
I) testing a hESC-derived cell therapy by Geron [2], and
two other trials recently approved by the FDA by Advanced
Cell Technology Inc’s [3]. With the discovery of induced
pluripotent stem (iPS) cells [4], the opportunities of stem
cell research have grown exponentially [5]. For example, the
use of disease-in-a-dish models is accelerating the building
of platforms for drug screening [6]. Disease-speciﬁc iPS
cell lines are also oﬀering new platforms to increase the
understanding of the pathophysiology of complex diseases.
iPS research also oﬀers great promise for the ﬁeld of
personalized medicine as it will enable the generation of
autologous therapies [6]. Indeed, pluripotent stem cell is
now recognized as a valuable starting material for the
development of cell products and therapies, as exempliﬁed
by the increase of the pharmaceutical industry’s involvement
(andinvestment)inﬁeldsbeyondthetraditionalareaofstem
cells for drug discovery [7].
Given the scientiﬁc potential of the stem cell ﬁeld, stem
cell banks are an essential resource of biological materials for
both basic and translational research [8]. According to the
Organisation for Economic Co-operation and Development
(OECD), advances in regenerative medicine and stem cells
are leading to the development of a bioeconomy: “a world
where biotechnology contributes to a signiﬁcant share of
economic output” [9]. Consequently, stem cell banks are
destined to constitute a pillar of the bioeconomy in many
countries. Indeed, in 2009, Time magazine recognized
“biobanks” generally as one of the “top 10 ideas changing the
world” [10].
Stem cell banks and registries support transnational
access to quality-controlled and ethically sourced stem cell2 Stem Cells International
lines from diﬀerent origins and of varying grades (e.g., re-
search versus clinical). They are also the “de facto”d e p o -
sitories of “biological standards” [11].
The emergence of national stem cell banks [12]h a s
been accompanied by international initiatives seeking to
harmonize and standardize processes [13]f o rs t e mc e l l
research and banking [14]. These initiatives share the vision
of stem cell research as a global enterprise. Illustrative
of this trend are the projects launched by the ISCF’s
International Stem Cell Banking Initiative (ISCBI), UMASS
International Stem Cell Registry (ISCR), and the European
hESC Registry. Likewise, regulatory bodies are increasingly
developing policy frameworks for safe and eﬀective cell-
based therapies [15–17]. Until recently, these eﬀorts adopted
an “embryocentric” approach, leaving behind other timely
and promising sources, such as iPs cells, and stem cells
derived from placentas, amongst others. Today, the size and
diversity of the collections are growing, as witnessed by the
increasing number of registries of disease samples [18]a n d
iPs cell lines [18–21].
Given the growing interest in stem cell banking, it is
timely and important to examine key issues of governance,
regulatory and commercial frameworks, and the possibilities
and desirability of international governance in this ﬁeld. It is
beyond the scope of this paper to provide a comprehensive
analysis of the wide range of approaches and challenges to
these issues and their implications. Nonetheless, we seek to
provide an overview of the most pressing challenges facing
the governance of stem cells banks and the challenges of
designing regulatory and commercial frameworks to foster
stem cell research.
2. From Registries to Biorepositories: Stem Cell
BankinginaComparativePerspective
2.1. Banks and Registries: National and International Initia-
tives. Stem cell banks represent a collection of biological
materials (e.g., embryos, somatic tissues, etc.) and the
associated data stored within an organized system [22]. The
term “stem cell bank” can refer to a number of diﬀerent
banks and types of operations, as well as institutions [23]. It
can refer to a centralized institute that provides cell lines for
research (e.g., Singapore SCB), a national supply centre, or a
repository of stem cell lines for a broad range of researchers
(e.g., Indian National Centre for SC Science). Similarly, stem
cell banks range from public banks, such as the UKSCB and
the Spanish National SCB, to institutional banks (e.g., Stem
Cell Research Centre, Kyoto University) and commercial
banks (e.g., BioTime, etc.). Finally, the term “stem cell bank”
is often also used to refer to stem cell registries; these are
databases systematically cataloguing the scientiﬁc and ethical
provenance of stem cell lines, including the European hESC
Registry and the UMass ISCR. It is important to highlight
that both stem cell banks and registries have distinct yet
complementary scientiﬁc value. However, given their nature
(biorepository versus database), they encounter diﬀerent
challengespertainingtoissuesofgovernance,regulation,and
commercialization.Here,weusetheterm“stemcellbank”to
encompass all these typologies of banks.
Stem cell banks aim to ensure the quality, availability,
and ethical provenance of tissues, cells, or embryos used for
research and eventual therapies. Like other biorepositories,
stem cell banks have as a core objective to avoid redundancy
in research projects and to eliminate the need for the
collection and derivation of additional human materials.
Moreover, stem cell banks are encountering issues similar to
thosefoundininternationalbiobankingmoregenerally[24],
including institutional governance, informed consent and
privacy, secondary uses of samples, commercialization, with-
drawal,andaccess(openversuscontrolled).Bothfacesimilar
challenges of ensuring safety through traceability, while
protecting the autonomy and privacy of donors [25, 26].
Stem cell banks are challenged by a myriad of policy
frameworks relating to the permissibility of conducting
research [27]. The latter is of particular relevance to cell
lines of embryonic origin given the accompanying political
and moral controversies. Due to the heterogeneous nature of
current policy approaches and their lack of interoperability,
uncertainties remain concerning the legality of certain
practices, for instance, material derivation and distribution
[8]. Similar to biorepositories, these uncertainties relate to
the ethics of both national and cross-jurisdictional material
and data use.
Policy frameworks signiﬁcantly impact research environ-
ments, underscoring the importance of developing eﬀective,
adaptive, and prospective policies to manage the socioethical
and legal issues associated with the translational cycle [28].
Nevertheless, such an endeavor is challenging. For instance,
for both contemporary and emerging sources of stem cells
and their prospective or retrospective use, the need to resolve
important issues that remain controversial has intensiﬁed.
For instance, even when dealing with core ethical principles
[29] such as autonomy (e.g., informed consent, right to
withdraw), respect for privacy and conﬁdentiality (e.g.,
protection of donor identity given the need for traceability
of stem cell lines), and the noncommercialization of human
reproductive materials (e.g., translated into restrictions
on monetary compensation for gamete and other tissue
donation), the ethical and policy landscape remains largely
uncharted [30].
2.2. Stem Cell Banking: Governance. Governance has been
deﬁned as the exercise of authority within a given sphere.
It has been employed as a synonym for the eﬃcient
management of a broad range of organizations and activities
[31]. Current stem cell banking initiatives foresee, like the
immortal cells they curate, a long-term existence. In fact,
most platforms have been created for prospective banking,
research, and clinical applications. Although the scope and
governance structure of national stem cell banks and reg-
istries vary, they all accord importance to the centralization
of quality controlled and ethically sourced stem cell lines.
Likewise, they are committed to governance mechanisms
that promote transparency, stewardship, and accountability
to generate public support and trust.
Good governance should be understood at all lev-
els, from the initial institutionaldesign to the institution’sStem Cells International 3
performance. The process chosen to create, govern, and
evaluate the scientiﬁc and ethical integrity of the initiative
must also ensure the legitimacy of its raison d’ˆ etre [32].
Governance mechanisms act at two levels: at the internal
level through mechanisms governing the day to day activities
of the bank, and at the external level, by independently
assessing the overall bank performance and by making the
bank accountable to all its stakeholders.
The sustainability of stem cell banks and registries
depends on the implementation of governance mecha-
nisms that ensure their scientiﬁc and ethical integrity. In
order to achieve this goal, stem cell banks’ governance
structures, processes, and bodies must be independent,
accountable, and transparent [33]. Our previous research
has identiﬁed governance gaps and areas where a lack of
concerted eﬀort impedes transnational and translational
stem cell research [8]. In the context of embryonic stem
cell banking, our international comparative research has
demonstrated how the heterogeneous nature of national
socioethical and policy frameworks poses a signiﬁcant chal-
lenge to international cooperation, creating additional bur-
dens for innovators seeking to move across national borders
[34].
The transnational sharing of stem cell materials and
related data is largely dependent on the ability of institutions
and jurisdictions to harmonize practices with regards to nor-
mative and ethical principles, oversight, governance mech-
anisms, quality assurance, and scientiﬁc practices. While it
is recognized that “stem cell research is a global enterprise
that begins at the local level” [35], the majority of current
and emerging national stem cell banking initiatives do not
adopt a prospective governance strategy. Despite platforms
being built with the goal of maximizing reproducibility,
comparability, and transparency in the ﬁeld [36], they often
lack comprehensive, prospective, and transparent ethical
and governance frameworks. The absence of provisions
addressing the cross-jurisdictional sharing of stem cell lines
or intellectual property rights could potentially thwart the
advancement of research by limiting some transactions,
thereby narrowing the availability of cell lines, and conse-
quently, impacting the quality and nature of the research.
Accordingly, the adoption of interoperable quality assurance
standards and clear consent mechanisms for international
access, exchange, and governance is essential.
Stem cell banks across jurisdictions are experiencing
policy convergence with the adoption of common ethi-
cal principles and research governance requirements. For
instance, while informed consent requirements for stem cell
derivation, use, and banking have evolved along with the
pace of scientiﬁc developments, policy variations still exist
for both somatic and embryonic sources [37]. Similarly,
challenges exist with respect to mechanisms to protect the
privacy and conﬁdentiality of donors. For example, the
“virtual genetic identity between iPS and donor cells raises
particular concerns regarding respect for donors” especially
given the potential traceability of stem cell lines [38].
Likewise, the possibility of reprogramming such cells back
to their origins [39] reintroduces the “embryonic” issues.
Consequently, appropriate mechanisms and ethical and legal
approaches to solve challenges related to these socioethical
and policy issues are yet to be deﬁned for stem cell banking.
Reﬂecting the policy frameworks governing the permis-
sibility of conducting stem cell research in their respective
jurisdictions, stem cell banks have proposed or adopted
diﬀerent criteria with regard to depositing and accessing
stem cell lines [40]. These approaches consist of policies that
seek to create absolute ethical and legal equivalency (e.g.,
Czech Republic) or to establish reciprocal policy agreements
in order to grant ethical provenance of the cell lines (e.g.,
California CIRM, Canada CIHR, and UKSCB). A third, and
favored approach is use broad “substantially equivalent” or
“acceptably derived” criteria (US NAS and NIH, UKSCB)
[40].
Licensing requirements demonstrating provenance of
the stem cell line are the procedural mechanism with
the greatest impact on research. Nonetheless, very little
has been said with respect to the type of ethical review
and ongoing oversight that is required for long-term and
international infrastructures like stem cell banks. In terms of
provenance determination, across the board, stem cell banks
require proof of prior local ethical and scientiﬁc review and
approval, as well as compliance with licensing and regulatory
requirements by local entities. Similarly, provisions to assess,
review, or verify transnational practices in order to vouch for
the ethical, scientiﬁc, and legal provenance of a stem cell line
of foreign origin are only emerging. Given the international
realities of stem cell research, this gap in existing regula-
tory frameworks has the potential to constitute a serious
roadblock for seamless collaboration, and ultimately, for the
fulﬁllment of the goals of a stem cell bank itself [8].
Stem cell banking initiatives aim to interconnect national
eﬀorts in order to facilitate collaboration. However, access to
research needs to be streamlined and simpliﬁed [8]. Stem
cell banks exist to promote scientiﬁc advances and thereby
to respect the wishes of donors. The existence of multiple
andsometimesevencontradictoryethicsreview,undermines
the possibility of creating transparent and accountable gov-
ernance mechanisms by creating REB “mission creep” and
“reduces the likelihood that studies are in keeping with rele-
vant ethical standards” [41]. Thus, international governance
models, including collaborative ethics review models such as
those proposed by the 2010 Canadian TCPS [42] or by the
UK Academy of Medical Sciences [43]—provide illustrative
examples of the possibility of creating a proportionate,
consistent, eﬃcient, and coordinated approach to ethics
review, governance, and regulation. Promoting ethical stem
cell research is a delicate balancing act between minimizing
overregulation while still assuring adequate protection of
research subjects.
These issues have been highlighted by the recommen-
dations recently adopted by the Hinxton Group [44].
According to the Hinxton Group, both issues of governance
(i.e., licensing, ethics review, etc.) and access (to data and
samples) could be resolved with the establishment of a
centralized and comprehensive hub providing information
about provenance, governance, and intellectual property,
amongst other features. It is indeed the overall aim of
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the International Stem Cell Banking Initiative (ISCBI)
and the UMASS International Stem Cell Registry [45]t o
promote coordinated and harmonized eﬀorts of domestic
and international governance. Moreover, these initiatives
have been established with the objective of systematically
collecting, organizing, and disseminating cell-line speciﬁc
information. Most importantly, these initiatives all aim to
promote international collaboration with the establishment
ofaglobalandinteroperablenetworkofstemcellbanks[46].
To this end, the Hinxton Group’s call to “encourage, support
and coordinate human stem cell banks and tissue/cells
repositories” should be interpreted as a call to support the
sustainability of eﬀorts such as ISCBI and UMASS.
2.3. SC Banking: Regulatory Issues and Challenges. The reg-
ulatory framework for stem cell research is currently a com-
plex patchwork [47, 48], becoming increasingly complicated
as translational research brings new modes of governance
into play [49]. Researchers developing therapeutic applica-
tions for use in humans are subject to additional regulatory
requirements designed to ensure the safety, eﬃcacy, and
quality of such products. Regulatory uncertainty has been
identiﬁed as a signiﬁcant barrier to the commercialization
and utilization of regenerative medicine products [50–52].
With a wide range of stem cell clinical trials continuously
movingforward[53],theneedforclarityandharmonization
of national and international regulatory requirements is
gaining moment [54].
Eﬀectiveregulation isalsomademorediﬃcult bythefact
thatstemcell-basedproductsarediverse.Someclinicalappli-
cations using stem cells, for example in oncology, are well
established, whereas more novel interventions derived from
hESCs or induced pluripotent stem (iPS) cells carry distinct
risks, some of which are unpredictable [55–57]. Still, both
iPSCs and hESCs may face similar regulatory and technical
challenges in terms of their clinical translation [58]. Indeed,
across jurisdictions, regulatory requirements, including cri-
teria for donor eligibility and screening, together with levels
of oversight and governance, should be proportional to the
degree of risk, type of research (e.g., in vivo animal versus
human; in vitro animal versus human hCT/transplant) and
degree of donor/sample identiﬁability.
Regulatory agencies have the diﬃcult task of balancing
competing demands: avoiding overly intrusive regulation
that will impede innovation or restrict access to urgently
needed innovative therapies, while at the same time ensuring
that safety, eﬃcacy, and quality are maintained to protect
the public. Recent reports of serious adverse events have
renewed concerns about potential long-term safety issues
[59]. Concerns about “stem cell tourism” [60–62] highlight
the tension between demands for access to novel therapies
and the need for rigorous oversight of safety, eﬃcacy, and
quality. Overall, regulatory agencies have adopted a “risk-
based” approach to cell therapies and products, focusing
primarily on safety issues rather than on eﬃcacy matters
[54]. This risk-based approach deals with intrinsic (e.g.,
cell origin) and extrinsic factors such as donor selection
and sample procurement (e.g., limiting risk of transmission
of communicable diseases) to manufacturing and handling
practices (e.g., adverse events), amongst others [63].
In many countries [64], the legal framework and reg-
ulatory processes are being adapted to meet the challenge
of characterizing and regulating novel types of products
[52, 65, 66]. Around the world, countries from Germany
[67] to China [46, 68] are enacting legislation to regulate
cell and tissue therapies. Moreover, major regulatory reforms
have taken place in Europe [69–71], Australia, Canada [72],
and United States [73]. Furthermore, the International Stem
Cell Banking Initiative is undertaking a major endeavour
to standardize regulatory requirements with the adoption
of a “Points to Consider” for stem cell banks of clinical
grade hESC Lines. This “Points to Consider”—expected
to be released in late 2011—will cover a wide range of
processes involved in stem cell banking (e.g., procurement,
banking procedures and documentation, quality assurance,
and access processes). It will also establish technical require-
ments (release criteria, cell line characterization, traceability,
microbiological testing, and shipment). Moreover, it will
also address governance, provenance, informed consent,
oversight, and licensing.
Whileregulatoryframeworksforstemcelltranslationare
being reﬁned [74, 75], current regulatory uncertainty creates
barriers to the commercialization and clinical development
of cell therapies [76], thereby stressing the need for clear
and harmonized deﬁnitions of key concepts and terms
[77]. Even in the presence of ﬂexible legal frameworks
designed to facilitate innovation—such as those adopt-
ing a permissive approach towards research and clinical
applications—regulatorysystemscanstillbeinhibitors,espe-
cially when their onerous nature makes the transaction costs
of engaging with them disproportionate (i.e., burdensome
and unclear, lack of ﬁnancial incentives, etc.) or when the
international sharing has not been adequately addressed
[78].
Finally, existing regulatory frameworks ensure proper
methods for donation, procurement, processing, and preser-
vation of cells and tissues but are often based on standard
pharmaceutical paradigms. Given the unique characteristics
of stem cells to proliferate and diﬀerentiate, stem cell lines
present certain regulatory challenges for safety and eﬀective-
ness that diﬀer from other pharmaceutical products [79].
Regulatory agencies are entrusted with ensuring that only
safe, eﬀective, and quality therapies and products reach the
market. They are faced with competing goals: to establish a
delicatebalancebetweenpromotinginnovationandenabling
access to scientiﬁc advances, while also protecting the safety
and welfare of the public [80]. Regulators are challenged
by advocacy groups critical of what they perceive as overly
intrusive regulation that may delay or prevent access to
potentially beneﬁcial therapies [81]. At the same time,
regulatorsaretestedbysafetyconcerns,highlightedbyrecent
reports of serious adverse events following application of
certain stem cell interventions [82, 83]. These challenges
are also present in the context of stem cell banking as
stem cell banks can only be eﬀective if the lines they
curate have undergone rigorous screening, derivation, and
manufacturing processes [71].Stem Cells International 5
2.4. Stem Cell Banking: Commercialization. Stem cell bank-
ing raises numerous challenges with respect to downstream
commercialization, reﬂected by complex access agreements
and restrictions to future intellectual property rights (e.g.,
due to MTAs, informed consent, etc.). Similarly, com-
mercialization introduces challenges with regards to the
interests and rights of donors. Indeed, the discovery of novel
methods for stem cell line derivation (e.g., iPS cells) brought
a new approach to the commercialization and patenting
landscape [84]. Today, the patent thicket is looming with
iPS patents granted in Japan, the United Kingdom, and
the United States [85]. Likewise, broad patent applications
to the technology are pending in other countries such as
Canada [86]. The accompanying socioethical and political
controversies and expected legal challenges associated with
thegrantingandthescopeofsuchpatents[87]willinevitably
have repercussions for the stem cell banking ﬁeld, especially
asiPSbankscontinuetoproliferate(e.g.,WiCell,JapanRiken
BioResource Center, and Ontario Pluripotent iPS Facility).
What remains to be seen is whether the surge of iPS cells
will have negative consequences for the banking ﬁeld, as
researchers may consider the “new reality of pluripotency
as a cheap and plentiful commodity” not worth the costs
involved in the banking process [88]. Interestingly, patent
pools are slowly emerging in the context of iPS cell research
as illustrated by the granting of exclusive rights to iPS-related
technology between Kyoto University and iPierian Inc.
[89].
The current instability of ﬁnancial markets, the consider-
able time, and investments needed to both develop and com-
mercialize stem cell products, together with the high degree
ofuncertaintyaboutexpectedreturnoninvestments,haveall
contributed to private investors early reluctance to embrace
the ﬁeld [90, 91]. However, as with the patenting landscape,
private involvement and investment in the stem cell ﬁeld is
also increasingly growing. This is particularly prevalent in
iPSCs research, as shown by the surge of companies devel-
oping a wide range of products “from and for iPS cells” [92].
At the same time, private investors have begun to ques-
tion the open access ethos that has characterized national
stemcellbankinginitiatives [93].Thisisparticularlyrelevant
in jurisdictions in which depositing or registering a stem cell
line is a sine qua non requirement of compliance of funding
and/or licensing policies (e.g., United Kingdom, France,
Czech Republic, Spain, Japan, European hESC Registry, and
India). These requirements seek to ensure tight regulation
and appropriate governance, while at the same time ensuring
eﬀective pooling of resources among the scientiﬁc commu-
nity [8]. However, it has been argued that such policies,
while adopted in the public interest, have nonetheless the
potential to discourage private investment as well as the
development of commercially viable products and therapies.
To create an environment that would be more conducive to
private investment, it is important that stem cell banking
policies facilitate the sharing and eventual licensing of stem
cell lines and accompanying data for research. To that end,
agreements (i.e., MTA, MDA, RUL, etc.) need to be carefully
designed to encourage future research use and possible
commercialization of stem cell research downstream [94].
Fundamental uncertainties about intellectual property
ownership and other contractual restrictions in the design
of access policies for stem cell banks could prevent private
investors from adequately protecting their interests as they
could impede future commercialization [95]. To that end,
animportantdecisionwhendevelopingaccesspoliciesdevel-
oped by stem cell banks concerns limitations and ownership
of future intellectual property rights. These rights can often
be a source of dispute and of long negotiations between
private companies, funding bodies, and universities [96].
In Europe, the unresolved conﬂation of patent require-
ments with ethics and morality [97]c o u l d ,i fc o n t r a c t u a l l y
transposed to stem cell banking, create a major disincentive
for the private sector. Moreover, if the opinion of the
advocate general of the European Court of Justice was to
prevail [98], products derived from hESCs in Europe would
n o tb ep a t e n t a b l e .T h en e g a t i v ei m p l i c a t i o n sf o rb o t hc o m -
mercialization and clinical translation of this position would
be enormous and will extend beyond the European context.
While it is important that biobank access policies prevent
parasiticpatentingpractices,imposingsigniﬁcantlimitations
and conditions on future intellectual property rights could
have a negative impact on private uptake of academic
research. It will not be suﬃcient to develop institutional or
national stem cell banking policies that promote technology
transfer; these policies will also need to be suﬃciently
harmonized to permit large scale international research
projects [99]. Given the current nature of the stem cell
industry [100], upstream transfer strategies that are less than
optimally designed could slow down the transfer of promis-
ing research, or contribute to another breakdown in the
private development of stem cell research downstream [101].
Thus, to ensure optimal technology transfer of results, there
is a need to investigate the use of open access agreements
upstreamintheresearchprocessaswellastheimpactofthese
agreements on the ownership of patents downstream.
To this end, the Hinxton Group’s 2011 Statement
[44] encompasses ambitious recommendations seeking to
improve the transparency and management of both intellec-
tual property and commercial transactions, in order to foster
innovation. Their recommendations promote the adoption
of formal collaborative networks for stem cell banking,
including the collective handling of intellectual property.
They are a welcome reminder that the road towards the
global governance of stem cell research and banking is yet
to be traced.
3. Conclusion
Models of stem cell banking governance are beginning to
address the sharing of data and samples across borders from
the initial consent process to a system for evaluating and
monitoring access requirements, together with intellectual
property and commercialization issues [102]. While there
is an acceleration in activities across a broad typology of
biobanks [95], in practice access to samples and data is
oftenhindered,particularly“wheninteroperabilityissought,
speciﬁcrestrictionsconcealedinvariablepolicies,procedures
and contracts constitute an important hurdle” [103].6 Stem Cells International
Theinternationalprocessofreciprocalrecognitionputin
place following the adoption of the 1995 European Directive
may be a way to foster accountability, transparency, and
innovation in international stem cell banking governance
[33]. The recognition of laws, policies, and consent from
other countries as equivalent or at a minimum as substan-
tially equivalent underlies the safe harbor approach [33].
Another avenue is the adoption of reciprocal agreements
beyond the bilateral to the multilateral; however this too
can become a burdensome contractual tool. Evidently,
prospective harmonization and policy convergence is the
ideal. In this regard, good faith eﬀorts should begin now.
Such harmonization serves not only to make stem cell
banking eﬃcient butalso to respect the wishes of donors that
their biological materials actually serve research in real time.
More importantly, eﬀorts should be devoted to the chal-
lenges posed by social (i.e., distributive) justice issues related
to equitable beneﬁcence in terms of access to research and
eventual therapies. Reciprocity for participating individuals
and populations is an ethical imperative. A central step
towardsachievingthesegoalsistoensurediversityinorderto
accurately complete our modern societal mosaic. Diversity—
through the entire research cycle—should be understood
beyond proportionate ethnic representation, to encompass a
wide representation of health disorders and conditions.
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